Cover Image
市場調查報告書

巴西的醫藥品市場未來展望

Brazil Pharmaceutical Market Outlook 2018

出版商 RNCOS E-Services Pvt. Ltd. 商品編碼 321221
出版日期 內容資訊 英文 90 Pages
訂單完成後即時交付
價格
Back to Top
巴西的醫藥品市場未來展望 Brazil Pharmaceutical Market Outlook 2018
出版日期: 2014年12月14日 內容資訊: 英文 90 Pages
簡介

巴西是南美最大,全球整體中第5大醫藥品市場。政府的強力支援,巨大的醫療服務需求,成為市場成長的主要原因。全球各國的製藥企業,將巴西當作今後最有前途的市場推進著市場開拓。推動醫療服務整體的整備計劃,也對醫藥品市場成長有所貢獻。巴西的醫藥品市場規模推算為268億9000滿美金(2013年當時),還有2013∼2018年的年複合成長率(CAGR)達到14.5%。各部門中,成藥(一般藥)、學名藥的市場成長率非常高。還有國內大企業佔整體市場約50%。

本報告提供巴西的醫藥品市場相關分析、市場整體結構最新趨勢、主要的推動因素和應該解決的課題、政府的相關法規、政策、市場整體及各部門趨勢預測(今後5年份)、市場競爭狀態、企業合併、收購(M&A)的動向、主要企業簡介等調查、考察。

第1章 分析師的見解

第2章 分析方法

第3章 推動市場要素

  • 對醫療的公共、民間支出額
  • 臨床實驗數量的增加
  • 可支配所得的擴大
  • 人口的高齡化

第4章 市場課題

  • 藥物治療費用高
  • 進口藥的依賴情形
  • 嚴格的藥物認證、管理法
  • 稅負擔重

第5章 製藥產業概要

第6章 市場明細

  • OTC(一般用)醫藥品
    • 管理體制
  • 學名藥
  • 處方藥

第7章 巴西國內的疾病治療領域

  • 腫瘤
  • 感染疾病
  • 心血管疾病、糖尿病
  • 中樞神經系統(CNS)疾病

第8章 企業合併、收購(M&A)(2010年以後的大型議案)

第9章 競爭環境

  • 國內/外資型企業的市場佔有率
  • 整體市場佔有率的明細

第10章 主要企業

  • EMS
  • Hypermarcas
  • Ache Laboratories
  • Eurofarma
  • Sanofi-Aventis
  • F. Hoffmann La Roche
  • Novartis
  • Pfizer
  • Merck Group

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Brazil is considered as one of the most lucrative healthcare markets, accounting for the highest healthcare expenditure in Latin America. It is the largest pharmaceutical market in Latin America and the fifth largest globally. Strong government support and high healthcare services demand are two of the major factors propelling the country's pharmaceutical market. Drug makers are also keen to tap the Brazilian market because it is one of the most lucrative and fastest-growing pharma markets worldwide. Pharma companies such as Sanofi, Pfizer, Boehringer Ingelheim, Sun Pharma, GSK, etc., have been trying to expand their businesses in Latin America following acquisition of domestic manufactures.

The Brazilian Government has adopted several initiatives and implemented appropriate plans and policies that have resulted in the positive development of the country's overall healthcare services and facilities. In our latest research study "Brazil Pharmaceutical Market Outlook 2018", RNCOS' analysts have identified the market dynamics of major pharmaceutical segments such as Generics, OTC and Prescription Drugs. Accordingly, a study has been conducted for their current market sizes and forecasts for the next five years. The Pharmaceutical market, which stood at US$ 26.89 Billion in 2013, is expected to grow at a CAGR of 14.5% during 2013-2018.

RNCOS' analysis shows that the Over-the-Counter drug and Generic drug segments have been the fastest growing and are expected to surpass the branded medications market in the near future. Government support to encourage the domestic drug industry, rising healthcare expenditure, patent expiry, reduced taxations, high disposable incomes, etc., are few important drivers resulting in high growth in these segments. Further analysis includes current market statistics, key drivers stimulating each segment's growth, and future outlook of the segments.

EMS Pharma, Hypermarcas, Ache Laboratories, Eurofarma are the top four domestic pharma companies, with EMS Pharma and Ache Laboratories leading the Generics and Prescription Drug segments respectively. These companies contributed around 50% of the domestic pharmaceutical market in 2013. Among the foreign players, Sanofi, Novartis and Roche have been generating a significant amount of revenue from the Brazilian market since the last three years.

The report, covers all the necessary aspects of the Brazilian Pharmaceutical market, providing an in-depth research and prudent analysis of the key segments. The topics covered in the report include: Pharmaceutical Production, Prescription Segment, OTC Segment, Therapeutic Segment as well as Mergers and Acquisitions. The report also presents an insight into the current industry trends, key market drivers, and government initiatives to enable the clients understand the market structure and its growth during the forecasted period. The report also covers detailed information about active market players in the Brazil pharmaceutical industry, including domestic and foreign players.

Table of Contents

1. Analyst View

2. Research Methodology

3. Market Drivers

  • 3.1 Public and Private Expenditure on Healthcare
  • 3.2 Rising Number of Clinical Trials
  • 3.3 Rising Disposable Income
  • 3.4 Ageing Population

4. Market Challenges

  • 4.1 High Prices of Medications
  • 4.2 Dependence on Imported Drugs
  • 4.3 Stringent Drug Licensing and Regulatory Laws
  • 4.4 High Tax Burden

5. Pharmaceutical Industry Overview

6. Market Segmentation

  • 6.1 OTC Drug
    • 6.1.1 Regulatory Framework
  • 6.2 Generics
    • 6.2.1 Regulatory Framework
  • 6.3 Prescription Drug
    • 6.3.1 Regulatory Framework

7. Therapeutic Segments in Brazil

  • 7.1 Oncology
  • 7.2 Infectious Diseases
  • 7.3 Cardiovascular and Diabetes
  • 7.4 CNS Diseases

8. Mergers and Acquisitions (Premium Deals since 2010)

9. Competitive Landscape

  • 9.1 Share of Domestic Vs International Players
  • 9.2 Overall Market Share Breakdown

10. Key Players

  • 10.1 EMS
  • 10.2 Hypermarcas
  • 10.3 Ache Laboratories
  • 10.4 Eurofarma
  • 10.5 Sanofi-Aventis
  • 10.6 F. Hoffmann La Roche
  • 10.7 Novartis
  • 10.8 Pfizer
  • 10.9 Merck Group

List of Figures:

  • Figure 3-1: Expenditure on Health (% of GDP), 2008-2013
  • Figure 3-2: Total Expenditure on Health per capita (PPP int.US$), 2008-2013
  • Figure 3-3: Share of Government and Private Expenditure (2012)
  • Figure 3-4: Government Expenditure on Health (% of total expenditure), 2008-2012
  • Figure 3-5: Private Expenditure on Health (% of total expenditure), 2008-2012
  • Figure 3-6: Number of Clinical Trials (2008-2014)
  • Figure 3-7: Annual Disposable Income (Million US$), 2010-2014
  • Figure 3-8: Disposable Income Brackets (%), 2012
  • Figure 3-9: Population above 65 Years (Million), 2008-2013
  • Figure 5-1: Share of Brazilian Pharmaceutical Market in Latin America (2013)
  • Figure 5-2: Pharmaceutical Production (Million US$), 2011-2013
  • Figure 5-3: Pharmaceutical Production Share by Use (2013)
  • Figure 5-4: Pharmaceutical Production by Use (Million US$), 2012 & 2013
  • Figure 5-5: Pharmaceutical Production by Ingredients (Million US$), 2012 & 2013
  • Figure 5-6: Pharmaceutical Production Share by Ingredients (2013)
  • Figure 5-7: Pharmaceutical Trade (Million US$), 2011-2013
  • Figure 5-8: Pharmaceutical Market (Billion US$), 2013-2018
  • Figure 5-9: Pharmaceutical Sales Volume (Billion Units), 2008-2013
  • Figure 6-1: Pharmaceutical Market Share by Segments (2013)
  • Figure 6-2: Pharmaceutical Market Share by Segments (2018)
  • Figure 6-3: OTC Drugs Market (Billion US$), 2013-2018
  • Figure 6-4: OTC Market Segmentation by Category (2013)
  • Figure 6-5: Generics Market (Billion US$), 2013-2018
  • Figure 6-6: Generics Drug Sales by Volume (Million Units), 2008-2013
  • Figure 6-7: Generics Drug Laboratories (2010-2013)
  • Figure 6-8: Generics Drug Market by Country of Origin (%), 2013
  • Figure 6-9: Number of Generics Drugs Registered by Company (2013)
  • Figure 6-10: Prescription Drugs Market Segmentation (2013)
  • Figure 6-11: Prescription Drugs Market (Billion US$), 2013-2018
  • Figure 7-1: Number of HIV Cases Registered ('000), 2005 & 2013
  • Figure 7-2: HIV Infection Rate in Adult Population (%), 2013 & 2030
  • Figure 7-3: Diabetic Patients in Age Group 20-79 Years (Million), 2013 & 2030
  • Figure 9-1: Share of Domestic and International Players (2013)
  • Figure 9-2: Market Share of Leading Players in Brazilian Pharmaceutical Market (2013)
  • Figure 10-1: Hypermarcas - Revenue Share by Business Segments (2013)
  • Figure 10-2: Ache Laboratories - Revenue Share by Business Segments (2013)
  • Figure 10-3: Sanofi-Aventis - Revenue by Business Segments (Million US$), 2012 & 2013
  • Figure 10-4: Sanofi-Aventis - Revenue Share by Geographical Regions (2013)
  • Figure 10-5: Sanofi-Aventis - Revenue Share by Different Regions in Emerging Market (2013)
  • Figure 10-6: Roche - Revenue Share by Business Segments (2013)
  • Figure 10-7: Roche - Revenue Share by Therapeutic Segments (2013)
  • Figure 10-8: Roche - Pharmaceutical Revenue Share by Geographical Regions (2013)
  • Figure 10-9: Novartis - Revenue Share by Business Segments (2013)
  • Figure 10-10: Novartis - Pharmaceutical Revenue Share by Geographical Regions (2013)
  • Figure 10-11: Pfizer - Revenue Share by Business Segments (2013)
  • Figure 10-12: Pfizer - Revenue Share by Geographical Regions (2013)
  • Figure 10-13: Merck Group - Revenue Share of Biopharmaceuticals by Geographic Regions (2013)
  • Figure 10-14: Merck Group - Revenue Share of OTC by Geographic Regions (2013)

List of Tables:

  • Table 3-1: Household Disposable Income Brackets ('000), 2012
  • Table 5-1: Ranking of Medications by Sales (2013)
  • Table 6-1: Number of Generics Drugs by Country (2013)
  • Table 7-1: Prevalence of Overweight and Obesity by Gender (%), 2013
  • Table 10-1: Hypermarcas - Revenue by Business Segments (Million US$), 2012 & 2013
  • Table 10-2: Ache Laboratories - Revenue by Business Segments (Million US$), 2012 & 2013
  • Table 10-3: Novartis - Revenue by Business Segments (Million US$), 2012 & 2013
  • Table 10-4: Pfizer - Revenue by Business Segments (Million US$), 2012 & 2013
  • Table 10-5: Merck Group - Revenue by Business Segments (Million US$), 2012 & 2013
Back to Top